Menu

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (3759)

Company Market Cap Price
GILD Gilead Sciences, Inc.
Trodelvy is a TROP2-targeted antibody-drug conjugate (ADC), a core oncology modality.
$158.22B
$127.53
+0.32%
BSX Boston Scientific Corporation
Directly sells Cardiology Devices (e.g., WATCHMAN LAAC, ablation catheters, stents) and other interventional cardiology therapies.
$149.60B
$100.97
-0.39%
PFE Pfizer Inc.
Pfizer's vaccines portfolio (e.g., Comirnaty and other RSV vaccines) is a core, revenue-driving product line.
$146.18B
$25.70
-0.10%
SYK Stryker Corporation
Stryker directly manufactures surgical devices and instruments used in operating rooms.
$142.33B
$372.28
-0.75%
WELL Welltower Inc.
Healthcare Services & Facilities – Welltower's properties function as healthcare facilities and related operations.
$137.95B
$206.28
+0.82%
MDT Medtronic plc
Medtronic's core cardiovascular devices include leadless pacing, ablation technologies, and related interventional products.
$134.71B
$105.02
-0.31%
HCA HCA Healthcare, Inc.
HCA operates a large network of hospitals and provides inpatient hospital services.
$120.45B
$514.67
-0.23%
VRTX Vertex Pharmaceuticals Incorporated
Vertex is a large-cap pharma/biotech with a diversified, revenue-generating portfolio anchored by CFTR modulators and expanding pipeline.
$110.80B
$432.20
+0.55%
MCK McKesson Corporation
McKesson distributes medical devices and biometrics through its Medical-Surgical Solutions, aligning with the medical devices category.
$109.92B
$884.77
-0.51%
CVS CVS Health Corporation
CVS Health includes health benefits/insurance via Aetna, a core health insurance offering.
$101.29B
$79.88
+1.80%
BMY Bristol-Myers Squibb Company
Opdivo is a monoclonal antibody immuno-oncology therapy, a core direct product in BMY's Growth Portfolio.
$100.25B
$49.25
+0.41%
WM Waste Management, Inc.
WM Healthcare Solutions provides regulated medical waste management and secure information destruction services.
$87.56B
$217.31
+0.50%
REGN Regeneron Pharmaceuticals, Inc.
Regeneron’s core business centers on monoclonal antibody therapeutics (e.g., Dupixent, Libtayo).
$83.16B
$784.81
-0.32%
ELV Elevance Health Inc.
Direct health insurance provider (Health Insurance) – Elevance Health's core revenue comes from health benefits and risk-sharing with members.
$76.23B
$338.55
+0.68%
CI Cigna Corporation
Health insurance products and related services are CI's core offering.
$74.30B
$278.37
+0.06%
MFC Manulife Financial Corporation
Health insurance products via group/employee benefits segments.
$60.86B
$34.73
-0.74%
IDXX IDEXX Laboratories, Inc.
IDEXX manufactures in-clinic diagnostic instruments and related software (e.g., VetLab analyzers, Catalyst) and provides point-of-care diagnostics.
$60.48B
$756.04
-1.39%
AFL Aflac Incorporated
Aflac sells health-related supplemental insurance (e.g., cancer insurance) as a core product, aligning with Health Insurance.
$59.13B
$110.57
-0.95%
ALNY Alnylam Pharmaceuticals, Inc.
Alnylam's core product modality is RNA interference (RNAi) therapeutics, including approved products AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
$58.35B
$445.07
+3.55%
← Previous
1 2 3 4 ... 38
Next →
Showing page 2 of 38 (3759 total stocks)

Loading company comparison...

Loading research report...

BMY Bristol-Myers Squibb Company

European Commission Grants Approval for Bristol‑Myers Squibb’s Breyanzi in Mantle Cell Lymphoma

Nov 25, 2025
CI Cigna Corporation

Cigna Expands Advanced Imaging Network with Empire State Radiology Agreement

Nov 25, 2025
REGN Regeneron Pharmaceuticals, Inc.

Regeneron Secures EU Approval for Dupixent in Chronic Spontaneous Urticaria

Nov 25, 2025
BMY Bristol-Myers Squibb Company

Texas Attorney General Files Lawsuit Against Bristol‑Myers Squibb and Sanofi Over Plavix Efficacy Claims

Nov 22, 2025
PFE Pfizer Inc.

FDA Approves PADCEV and Keytruda Combination for Muscle‑Invasive Bladder Cancer

Nov 22, 2025
ALNY Alnylam Pharmaceuticals, Inc.

NICE Approves Alnylam’s AMVUTTRA for Heart Disease in England and Wales

Nov 21, 2025
REGN Regeneron Pharmaceuticals, Inc.

Regeneron Secures FDA Approval for Expanded EYLEA HD Dosing, Strengthening Market Position

Nov 20, 2025
PFE Pfizer Inc.

Pfizer Settles Texas Quality‑Control Claims for $41.5 Million

Nov 19, 2025
REGN Regeneron Pharmaceuticals, Inc.

Regeneron Secures EU Approval for Libtayo as First Immunotherapy in Adjuvant Treatment of High‑Risk Cutaneous Squamous Cell Carcinoma

Nov 19, 2025
BMY Bristol-Myers Squibb Company

Bristol‑Myers Squibb Accelerates Debt Repurchase, Settles Tender Offers Ahead of Schedule

Nov 18, 2025
GILD Gilead Sciences, Inc.

Gilead Ships First Lenacapavir Batches to Eswatini and Zambia

Nov 18, 2025
HCA HCA Healthcare, Inc.

HCA HealthONE Rose Adopts Perimeter’s S‑Series OCT Imaging to Enhance Surgical Precision

Nov 18, 2025
MDT Medtronic plc

Medtronic Beats Q2 FY2026 Earnings, Raises Full‑Year Guidance on Strong Cardiac Ablation Growth

Nov 18, 2025
BMY Bristol-Myers Squibb Company

Bristol‑Myers Squibb Halts Phase 3 Milvexian Trial in Acute Coronary Syndrome

Nov 15, 2025
BMY Bristol-Myers Squibb Company

Bristol‑Myers Squibb Halts Milvexian ACS Trial, Shifts Cardiovascular Strategy

Nov 14, 2025
GILD Gilead Sciences, Inc.

Gilead Reports Successful Phase 3 ARTISTRY‑1 Trial for Bictegravir/Lenacapavir Single‑Tablet HIV Regimen

Nov 14, 2025
PFE Pfizer Inc.

Pfizer Sells Majority Stake in BioNTech, Signaling Shift Away from COVID‑19 Vaccine Business

Nov 14, 2025
BMY Bristol-Myers Squibb Company

Bristol‑Myers Squibb Expands Collaboration with Sarah Cannon Research Institute to Accelerate Oncology Trials

Nov 13, 2025
PFE Pfizer Inc.

Pfizer Finalizes $10 B Acquisition of Metsera, Strengthening Obesity Portfolio

Nov 13, 2025
MDT Medtronic plc

Medtronic Announces Three‑Year Digital‑Health Partnership with Minze Health to Expand Overactive Bladder Support in EMEA

Nov 12, 2025
CI Cigna Corporation

Cigna Healthcare Teams with Headspace to Deliver Free Digital Mental‑Health Tools to 7 Million Members

Nov 10, 2025
REGN Regeneron Pharmaceuticals, Inc.

UK High Court Ruling Clears Path for Alvotech’s AVT06 Biosimilar, Threatening Regeneron’s Eylea Franchise

Nov 10, 2025
VRTX Vertex Pharmaceuticals Incorporated

Vertex Reports Strong 48‑Week Data for Povetacicept in IgA Nephropathy and Primary Membranous Nephropathy

Nov 09, 2025
PFE Pfizer Inc.

Pfizer Finalizes $10 Billion Acquisition of Metsera in Amended Merger Agreement

Nov 08, 2025
GILD Gilead Sciences, Inc.

Gilead’s Trodelvy Fails to Meet Primary Endpoint in First‑Line HR+/HER2‑Negative Breast Cancer Trial

Nov 07, 2025
PFE Pfizer Inc.

Pfizer Matches Novo Nordisk’s $10 B Bid for Obesity Biotech Metsera in Bidding War

Nov 07, 2025
REGN Regeneron Pharmaceuticals, Inc.

Regeneron Secures FDA Priority Review for Dupixent in Allergic Fungal Rhinosinusitis

Nov 07, 2025
BMY Bristol-Myers Squibb Company

Bristol‑Myers Squibb Issues €5 Billion Senior Unsecured Notes to Fund Tender Offer and Strengthen Debt Profile

Nov 06, 2025
ALNY Alnylam Pharmaceuticals, Inc.

Royalty Pharma Acquires 1% Royalty Interest in Alnylam’s AMVUTTRA for $310 Million

Nov 05, 2025
BMY Bristol-Myers Squibb Company

Bristol‑Myers Squibb Launches $7 Billion Cash Tender Offer to Repurchase Senior Notes

Nov 04, 2025
PFE Pfizer Inc.

Pfizer Beats Q3 2025 Earnings, Raises Full‑Year Guidance Amid COVID Product Decline

Nov 04, 2025
VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Reports Q3 2025 Earnings, Raises Full‑Year Guidance

Nov 04, 2025
IDXX IDEXX Laboratories, Inc.

IDEXX Laboratories Reports Q3 2025 Earnings, Raises Full‑Year Guidance

Nov 03, 2025
PFE Pfizer Inc.

Pfizer Files Second Lawsuit Against Metsera and Novo Nordisk Over Antitrust Concerns

Nov 03, 2025
ALNY Alnylam Pharmaceuticals, Inc.

Alnylam Reports Record Q3 2025 Earnings, Driven by Amvuttra Launch

Oct 31, 2025
BMY Bristol-Myers Squibb Company

Bristol‑Myers Squibb Reports Q3 2025 Earnings, Raises Full‑Year Revenue Outlook

Oct 31, 2025
ALNY Alnylam Pharmaceuticals, Inc.

Alnylam Receives U.S. Attorney Subpoena Over Distributor Fee and Discount Arrangements; Reports Record Q3 2025 Earnings

Oct 30, 2025
BMY Bristol-Myers Squibb Company

Bristol‑Myers Squibb Reports Q3 2025 Earnings, Raises Full‑Year Revenue Guidance to $47.5‑$48.0 Billion

Oct 30, 2025
CI Cigna Corporation

Cigna Beats Q3 Profit Estimates Driven by Evernorth Health Services Strength

Oct 30, 2025
SYK Stryker Corporation

Stryker Reports Q3 2025 Earnings, Raises Full‑Year Guidance

Oct 30, 2025
CI Cigna Corporation

Cigna's Evernorth to Eliminate Drug Rebates in Many Commercial Plans by 2027

Oct 27, 2025
CI Cigna Corporation

Cigna Approves Coverage for Cleerly LABS AI Cardiovascular Imaging Technology

Sep 30, 2025
CI Cigna Corporation

Cigna Reports Flat Employer Coverage for Weight-Loss Drugs Despite Demand Uptick

Sep 10, 2025
CI Cigna Corporation

Cigna's Evernorth Invests $3.5 Billion in Specialty Pharmacy Company Shields Health

Sep 02, 2025
CI Cigna Corporation

Cigna Expands Flexible Dental Payment Solution to 2.8 Million Additional Members

Aug 05, 2025
CI Cigna Corporation

Cigna Reports Q2 2025 Results, Beats Revenue Estimates Amid Cost Pressures

Jul 31, 2025
CI Cigna Corporation

Federal Judge Halts Arkansas Law Banning PBM Pharmacy Ownership

Jul 30, 2025
CI Cigna Corporation

Aeroflow Health Partners with Cigna to Offer Nationwide Virtual Nutrition Services

Jul 22, 2025
CI Cigna Corporation

The Cigna Group Added to Russell 1000 Defensive Indices

Jun 30, 2025
CI Cigna Corporation

Cigna Enables Coverage for RhinAer® Treatment of Chronic Nasal Conditions

Jun 27, 2025

The most compelling investment themes are the ones nobody is talking about yet.

Every Monday, get three under-the-radar themes with catalysts, data, and stocks poised to benefit.

Sign up now to receive them!

Also explore our analysis on 5,000+ stocks